MARKET

KIN

KIN

Kindred Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.21
-0.01
-0.05%
Opening 13:08 06/22 EDT
OPEN
9.20
PREV CLOSE
9.21
HIGH
9.22
LOW
9.20
VOLUME
480.04K
TURNOVER
--
52 WEEK HIGH
9.28
52 WEEK LOW
3.200
MARKET CAP
416.74M
P/E (TTM)
-41.1673
1D
5D
1M
3M
1Y
5Y
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - KIN, SYKE, USCR, ONEM, QTS, MCF
/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire - PRF · 1d ago
Looking Into Kindred Biosciences's Return On Capital Employed
Kindred Biosciences (NASDAQ:KIN) reported Q1 sales of $2.40 million. Earnings fell to a loss of $9.17 million, resulting in a 11.54% decrease from last quarter. In Q4, Kindred Biosciences brought in $951.00 thousand in sales but lost $10.36 million in earn...
Benzinga · 4d ago
Insider Trends: Kindred Biosciences Insider Continues 90-Day Selling Trend
MT Newswires · 4d ago
Elanco Animal Health to Snap up Kindred Biosciences; Shares Soar
Elanco Animal Health (ELAN) inked a deal to acquire Kindred Biosciences (KIN), a biopharmaceutical company that develops novel pet therapeutics based on validated human targets, at $9.25 per share for a total consideration of $440 million. Shares of both c...
SmarterAnalyst · 5d ago
Lake Street Downgrades Kindred Biosciences to Hold from Buy, Adjusts Price Target to $9.25 from $12
MT Newswires · 5d ago
48 Biggest Movers From Yesterday
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront.
Benzinga · 5d ago
--HC Wainwright Downgrades Kindred Biosciences to Neutral From Buy, Adjusts Price Target to $9.25 From $9
MT Newswires · 5d ago
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Kindred Biosciences, Inc. (NASDAQ:KIN)
BALA CYNWYD, PA / ACCESSWIRE / June 16, 2021 / Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Kindred Biosciences, Inc. (“KindredBio” or the “Company”) (NASDAQ:KIN) for possible breaches ...
ACCESSWIRE · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KIN. Analyze the recent business situations of Kindred Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KIN stock price target is 10.50 with a high estimate of 15.25 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 128
Institutional Holdings: 32.72M
% Owned: 72.28%
Shares Outstanding: 45.27M
TypeInstitutionsShares
Increased
29
1.32M
New
12
5.48M
Decreased
25
2.36M
Sold Out
10
154.88K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.44%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
President/Chief Executive Officer/Director
Richard Chin
Chief Financial Officer/Secretary
Wendy Wee
Chief Scientific Officer
Hangjun Zhan
Director
Denise Bevers
Independent Director
Ernie Mario
Independent Director
Lyndon Lien
Independent Director
Nanxi Liu
Independent Director
Joseph McCracken
Independent Director
Herbert Montgomery
Independent Director
Raymond Townsend
Independent Director
Ervin Veszpremi
No Data
About KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Webull offers kinds of Kindred Biosciences Inc stock information, including NASDAQ:KIN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KIN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KIN stock methods without spending real money on the virtual paper trading platform.